NNIT Renews Agreement with Novo Nordisk
NNIT enters into a 6-year-agreement with Novo Nordisk, replacing and extending an existing infrastructure outsourcing contract between the two parties, covering global services including support and maintenance of Novo Nordisk's corporate IT infrastructure.
Copenhagen, Denmark - NNIT, a leading provider of IT services and consultancy, announces that it has signed an extension of its infrastructure outsourcing agreement with Novo Nordisk.
The estimated total value of the agreement amounts to approximately DKK 1bn and covers global services, including support and maintenance of Novo Nordisk's corporate IT infrastructure.
The agreement covers Novo Nordisk's global IT infrastructure and further supports the pharmaceutical company's cloud strategy.
"The agreement marks the continuation of a long and successful collaboration between Novo Nordisk and NNIT," says Jacob Hahn Michelsen, Senior Vice President, NNIT. He continues: "Novo Nordisk calls for very competitive solutions that have been tailored to the life science industry so we are proud to be able to match their high expectations."
By 2020, approximately 34 million diabetes patients worldwide will depend on Novo Nordisk medicine, and the global IT organization plays a key role in providing the IT infrastructure, systems and services needed to cater for this in an efficient, compliant and secure manner.
"By choosing NNIT as a partner we have secured effective and efficient IT for an organization, which is growing globally, while keeping ourselves ready to adopt the emerging technologies and build them into our solutions for tomorrow's business," explains Vincent Turgis, Chief Information Officer, at Novo Nordisk.
The agreement is effective as of January 1, 2017 and runs until end 2022, replacing the existing agreement, which was set to expire by the end 2017.
About NNIT
NNIT A/S is one of Denmark's leading IT service providers and consultancies. NNIT A/S offers a wide range of IT services and solutions to its customers, primarily in the life sciences sector in Denmark and internationally and to customers in the public, enterprise and finance sectors in Denmark. As of March 31, 2017 NNIT A/S had 2,868 employees. For more information please visit www.nnit.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
